Integrated BioPharma (INBP) Stock Statistics & Valuation Metrics

Integrated BioPharma has a market cap or net worth of $9.86M. The enterprise value is $11.24M.

Integrated BioPharma has 30,300,720 shares outstanding. The number of shares has decreased by -2.65% in one year.

Integrated BioPharma’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is 0.48%.

The current PE Ratio of Integrated BioPharma is 53.69. Integrated BioPharma’s PEG ratio is 2.88.

In the last 12 months, Integrated BioPharma had revenue of 50.32M and earned 112.00K in profits. Earnings per share was 0.00.

In the last 12 months, operating cash flow was 1.29M and capital expenditures -347.00K, giving a free cash flow of 941.00K billion.

Integrated BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―

Integrated BioPharma upcoming earnings date is Sep 11, 2025, After Close (Confirmed).

Integrated BioPharma as a current ratio of 2.92, with Debt / Equity ratio of 14.17%

In the past 12 months, Integrated BioPharma has paid 156.00K in taxes.

Integrated BioPharma EV to EBITDA ratio is 3.98, with an EV/FCF ratio of 15.73.

Integrated BioPharma has $2.96M in cash and marketable securities with $1.14M in debt, giving a net cash position of -$1.82M billion.

Gross margin is 8.01%, with operating margin of 0.50%, and net profit margin of 0.22%.

The average price target for Integrated BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―